| Breast Cancer |
1 |
1 |
| Triple Negative Breast Cancer |
0 |
0.79 |
| Breast Cancer History |
0 |
0.77 |
| HER2-Positive Breast Cancer |
0 |
0.77 |
| Cancer |
0 |
0.75 |
| Biologic Therapy |
0 |
0.63 |
| Antineoplastic Drug |
0 |
0.57 |
| Breast |
0 |
0.57 |
| Cancer Risk |
0 |
0.56 |
| Liquid Biopsy |
0 |
0.56 |
| Pancreatic Cancer |
0 |
0.56 |
| Targeted Cancer Therapy |
0 |
0.55 |
| Healthcare and Medical Technology |
0 |
0.49 |
| Genomic Medicine |
0 |
0.48 |
| Clinical Research |
0 |
0.26 |
| Artificial Intelligence |
0 |
0.2 |
| Tumor |
0 |
0.09 |
| Receptors |
0 |
0.07 |
| Medical Life |
0 |
0.05 |
| Hospital |
0 |
0.04 |
| Humanized Monoclonal Antibody |
0 |
0.04 |
| Pregnancy |
0 |
0.04 |
| Racism |
0 |
0.04 |
| Social Determinants of Health |
0 |
0.04 |
| Washington |
0 |
0.04 |
| Treatment Guidelines |
0 |
0.03 |
| Antibody Drug Conjugates |
0 |
0.02 |
| Biomarker |
0 |
0.02 |
| Biopsy |
0 |
0.02 |
| Clinical Guidelines |
0 |
0.02 |
| Genetics |
0 |
0.02 |
| Hodgkin Lymphoma |
0 |
0.02 |
| Investment |
0 |
0.02 |
| Lung |
0 |
0.02 |
| Massachusetts |
0 |
0.02 |
| Medical Innovations |
0 |
0.02 |
| Michigan |
0 |
0.02 |
| North Carolina |
0 |
0.02 |
| Pennsylvania |
0 |
0.02 |
| Pharmacogenomics |
0 |
0.02 |
| Prognosis |
0 |
0.02 |